Reksod® (Rexod®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceSuperoxide dismutaseSuperoxide dismutase
Similar drugsTo uncover
  • Reksod®
    lyophilizate in / in 
    GosNII OCHB FMBA, FSUE     Russia
  • Reksod®
    solution in / in 
    GosNII OCHB FMBA, FSUE     Russia
  • Рексод®-ОФ
    lyophilizate d / eye 
    GosNII OCHB FMBA, FSUE     Russia
    • Dosage form: & nbsp
    Lyophilizate for the preparation of a solution for intravenous administration.
    Composition:1 ampoule (vial) contains 1.6 million ED or 3.2 million ED of human superoxide dismutase recombinant as the active substance.
    Description:
    Lyophilized powder or porous mass of white with a greenish or bluish tint of color.
    Pharmacotherapeutic group:Antioxidant.
    ATX: & nbsp

    S.01.X   Other drugs for the treatment of eye diseases

    Pharmacodynamics:Superoxide dismutase is an endogenous acceptor of free oxygen radicals, the excessive accumulation of which in the cell plays an important role in the development oxygen dependent pathological processes (hypoxia, inflammation, intoxication). Superoxide dismutase removes superoxide radicals and prevents the formation of other, more dangerous for the body radicals: hydroxyl radical and singlet oxygen. Besides, superoxide dismutase prevents the accumulation of inflammation in the focus, neutrophils, which secrete significant amounts of lysosomal enzymes that destroy nearby tissues.Rexod® normalizes the oxidative processes taking place with the participation of free radicals of oxygen and prevents the oxidative modification of proteins, as well as the destruction of biomembranes associated with the activation of lipid peroxidation.
    Pharmacokinetics:
    In intravenous administration of the drug Rexod®, the dynamics of its concentration in the blood correspond to the 2-chamber model. The half-life of the drug is about 30 ± 4 min. The ratio of stationary and initial volumes of distribution is of the order of 2, i.e., the drug is well distributed into tissues. Evidence of the accumulation of Rexod ® in the body and the possibility of its cumulation studies have not been revealed.

    Indications:Complex prophylaxis of development of intraoperative complications in endoprosthetics of large joints, using bone cement.
    Contraindications:
    Individual intolerance, age under 18, pregnancy, lactation.

    Dosing and Administration:
    Intravenously, drip, during surgery, before using bone cement. 9.6 million units of preliminarily dissolved in 100 ml of physiological solution for 10-15 minutes.
    The ready-made solution should be used immediately after preparation, not mixed with other medicinal products. The use of Rexod® is not a contraindication to the use of other drugs.

    Side effects:
    Allergic reactions are possible. For other preparations of superoxide dismutase, cases of development of anaphylactic reactions (including shock) have been described.

    Overdose:
    The drug is not toxic. Cases of overdose are unknown.

    Interaction:Clinically significant interactions of the drug are not described. In the endoprosthesis of large joints, the therapeutic efficacy of the drug is indicated by the combined administration of Rexod® with preparations of sodium fumarate.
    Form release / dosage:
    Lyophilizate for the preparation of a solution for intravenous administration in ampoules or vials of 1.6 million units or 3.2 million units.


    Packaging:
    5 bottles in a cardboard pallet with partitions, 1 cardboard pallet in a cardboard bundle with instructions for medical use. 5 ampoules in a cassette contour pack, 1 cassette contour mesh package in a cardboard box with instructions for medical use.

    Storage conditions:
    At a temperature of 4 to 10 ° C. Keep out of the reach of children.

    Shelf life:
    2 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-007164/09
    Date of registration:10.09.2009
    The owner of the registration certificate:GosNII OCHB FMBA, FSUE GosNII OCHB FMBA, FSUE Russia
    Manufacturer: & nbsp
    Information update date: & nbsp07.09.2015
    Illustrated instructions
      Instructions
      Up